@prefix this: . @prefix sub: . @prefix beldoc: . @prefix rdfs: . @prefix rdf: . @prefix xsd: . @prefix dct: . @prefix dce: . @prefix pav: . @prefix np: . @prefix belv: . @prefix prov: . @prefix Protein: . @prefix hgnc: . @prefix geneProductOf: . @prefix obo: . @prefix occursIn: . @prefix species: . @prefix pubmed: . @prefix orcid: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { sub:_1 geneProductOf: hgnc:11766; a Protein: . sub:_2 geneProductOf: hgnc:3778; a Protein: . sub:_3 occursIn: obo:CL_0000057, species:9606; rdf:object sub:_2; rdf:predicate belv:increases; rdf:subject sub:_1; a rdf:Statement . sub:assertion rdfs:label "p(HGNC:TGFB1) -> p(HGNC:FN1)" . } sub:provenance { beldoc: dce:description "Approximately 61,000 statements."; dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved."; dce:title "BEL Framework Large Corpus Document"; pav:authoredBy sub:_5; pav:version "20131211" . sub:_4 prov:value "Primary human bronchial mesenchymal fibroblasts were stimulated with 2.5 ng/ml TGF?1 for 48 h in the presence and absence of simvastatin (Figures 1A and 1B). TGF?1 induced a marked increase in fibronectin protein, an effect significantly suppressed by 1 (69.5 ± 7.4% of C), 10 (62.5 ± 6.7% of C) and 15 ?M (37.6 ± 11.5% of C) simvastatin. "; prov:wasQuotedFrom pubmed:21864337 . sub:_5 rdfs:label "Selventa" . sub:assertion prov:hadPrimarySource pubmed:21864337; prov:wasDerivedFrom beldoc:, sub:_4 . } sub:pubinfo { this: dct:created "2014-07-03T14:33:41.632+02:00"^^xsd:dateTime; pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 . }